This site is intended for healthcare professionals

Merck announces KEYNOTE-598 trial evaluating Keytruda plus ipilimumab versus Keytruda monotherapy for metastatic non-small cell lung cancer to stop for futility and patients to discontinue.

Read time: 1 mins
Last updated:12th Nov 2020
Published:13th Nov 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest